Eli Lilly

Obesity, diabetes drugs push Novo Nordisk and Eli Lilly to front of pharma's growth pack in Q2
Fierce Pharma
Wed, 08/16/23 - 10:05 am
Novo Nordisk
Eli Lilly
obesity
diabetes
earnings
Eli Lilly and Company completes acquisition of Versanis Bio
Pharmaceutical Business Review
Tue, 08/15/23 - 10:01 am
Eli Lilly
Versanis Bio
M&A
Eli Lilly raises full-year guidance as Mounjaro, other drugs drive second-quarter profit up 85%
CNBC
Tue, 08/8/23 - 11:43 am
Eli Lilly
earnings
Mounjaro
Report: Fewer Adults Are Interested in Weight Loss Drugs If Not Covered by Insurance
MedCity News
Mon, 08/7/23 - 11:12 pm
insurance
weight loss
payers
Novo Nordisk
Eli Lilly
Eli Lilly meets primary endpoint in LIBRETTO-431 study for NSCLC
Clinical Trials Arena
Mon, 08/7/23 - 10:25 am
Eli Lilly
clinical trials
Retevmo
non-small cell lung cancer
Keytruda
Novo Nordisk, Eli Lilly face injury lawsuit from user of popular GLP-1 medicines
Fierce Pharma
Thu, 08/3/23 - 06:44 pm
Novo Nordisk
Eli Lilly
Mounjaro
Ozempic
legal
side effects
Spotlight – Nash in 2023 and beyond
EP Vantage
Thu, 08/3/23 - 10:03 am
NASH
Boehringer Ingelheim
Zealand Pharma
Akero Therapeutics
Axcella Health
Eli Lilly
Pfizer
Ionis Pharmaceuticals
Cascade
AstraZeneca
Gilead Sciences
Novo Nordisk
Ascletis Pharma
MediciNova
Lilly's obesity drug leads to about 26% weight loss in new studies
Yahoo/Reuters
Thu, 07/27/23 - 11:41 am
Eli Lilly
obesity
clinical trials
Mounjaro
Eli Lilly's Mounjaro shortage worsens ahead of potential obesity FDA approval
Fierce Pharma
Wed, 07/26/23 - 11:26 am
Eli Lilly
Mounjaro
obesity
weight loss
drug shortages
Jardiance cleared in EU for CKD, challenging Forxiga
Pharmaphorum
Wed, 07/26/23 - 09:45 am
Boehringer Ingelheim
Eli Lilly
Jardiance
Europe
chronic kidney disease
Forxiga
New weight loss drugs carry high price tags and lots of questions for seniors
Medical Marketing and Media
Tue, 07/25/23 - 08:53 pm
Seniors
Wegovy
Novo Nordisk
Mounjaro
Eli Lilly
weight loss
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
BioSpace
Mon, 07/24/23 - 09:57 am
neurodegenerative disease
Alzheimer's disease
Axsome Therapeutics
Eli Lilly
Anavex
TauRx
AB Science
ALS
BrainStorm Cell Therapeutics
Seelos Therapeutics
Parkinson's Disease
AbbVie
Mitsubishi Tanabe Pharma
Annovis
Huntington's disease
Prilenia Therapeutics
Neurocrine
Novo Nordisk, Eli Lilly and Boehringer Ingelheim back bill to bring obesity drug coverage to Medicare
Fierce Pharma
Thu, 07/20/23 - 09:42 pm
Novo Nordisk
Eli Lilly
Boehringer Ingelheim
obesity
Lilly’s donanemab flaunts strong clinical profile, ready to compete with Leqembi
Clinical Trials Arena
Wed, 07/19/23 - 10:27 am
Eli Lilly
donanemab
Eisai
Biogen
Leqembi
Alzheimer's disease
Eli Lilly partners with Team U.S.A. through 2028 Olympic Games in Los Angeles
Medical Marketing and Media
Mon, 07/17/23 - 06:52 pm
Eli Lilly
Olympics
pharma marketing
Lilly shares full pivotal data on Alzheimer’s drug, revealing how it shapes up against Leqembi
Fierce Biotech
Mon, 07/17/23 - 06:51 pm
Eli Lilly
Alzheimer's disease
clinical trials
FDA
donanemab
AbbVie, Lilly-backed Capsida cuts staff months after signing Big Pharma deals
Fierce Biotech
Sun, 07/16/23 - 02:37 pm
Capsida Biotherapeutics
layoffs
gene therapy
AbbVie
Eli Lilly
Hungry for more, Lilly tops off weight loss pipeline with $1.9B deal to acquire Versanis
Fierce Biotech
Fri, 07/14/23 - 10:10 am
Eli Lilly
M&A
obesity
Versanis
bimagrumab
Lilly, Novo, BMS return to boost BGV's largest European biotech fund yet
Fierce Biotech
Thu, 07/13/23 - 10:15 am
Eli Lilly
Novo Holdings
Bristol Myers Squibb
venture capital
funding
BGV
Europe
After First Approval, Experts Point to Barriers in Cell Therapy for Type 1 Diabetes
BioSpace
Thu, 07/13/23 - 10:11 am
CellTrans
Lantidra
type 1 diabetes
cell therapy
Eli Lilly
Siglion Therapeutics

Pages